The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any …
DDM Ross, A Grigg, A Schwarer, C Arthur, K Loftus… - Blood, 2008 - Elsevier
After 5 years of imatinib treatment 40–50% of chronic myeloid leukaemia (CML) patients will
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …
[HTML][HTML] Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients.
FX Mahon, D Rea, F Guilhot, F Huguet, FE Nicolini… - Blood, 2009 - Elsevier
Abstract Abstract 859 Background Imatinib (IM) has greatly improved survival rates in
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …
Discontinuation of imatinib therapy in chronic myeloid leukemia patients with sustained complete molecular response4. 5 (CMR4. 5)
Abstract Abstract 2763 Approximately 50% of CP CML patients achieve complete molecular
response (CMR) at 6–7 years of first-line imatinib therapy. Although imatinib therapy is …
response (CMR) at 6–7 years of first-line imatinib therapy. Although imatinib therapy is …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA …
Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
[HTML][HTML] Imatinib Mesylate Discontinuation in Patients with Chronic Myelogenous Leukaemia in Complete Molecular Remission for More Than Two Years.
P Rousselot, F Huguet, JM Cayuela, O Maarek, G Marit… - Blood, 2005 - Elsevier
Abstract Background. Imatinib mesylate (IM, Gleevec®) induces cytogenetic remission
(CCR) defined as the disappearance of Philadelphia (Ph) chromosome-positive …
(CCR) defined as the disappearance of Philadelphia (Ph) chromosome-positive …
[HTML][HTML] A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic …
FX Mahon, S Dulucq, F Guilhot, L Legros, P Rousselot… - Blood, 2010 - Elsevier
Abstract 2298 We previously reported that imatinib treatment could be safely discontinued in
chronic myeloid leukemia (CML) patients who had achieved a sustained complete …
chronic myeloid leukemia (CML) patients who had achieved a sustained complete …
Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR/ABL? A case report and a review of the literature
S Guastafierro, U Falcone, M Celentano, M Coppola… - Leukemia research, 2009 - Elsevier
Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75–90%
of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage …
of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage …
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment
M Colombat, MP Fort, C Chollet, G Marit… - …, 2006 - haematologica.org
BACKGROUND AND OBJECTIVES: Imatinib mesylate induces a complete cytogenetic
response (CCR) in many patients with chronic myeloid leukemia (CML). However, the …
response (CCR) in many patients with chronic myeloid leukemia (CML). However, the …
[HTML][HTML] Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French Pilot Study and first results from the multicentre «Stop …
FX Mahon, F Huguet, F Guilhot, L Legros, FE Nicolini… - Blood, 2008 - Elsevier
Imatinib (IM) has greatly improved survival rates in chronic myeloid leukemia (CML).
However, all patients (pts) must continue treatment for an unknown period of time. A pilot …
However, all patients (pts) must continue treatment for an unknown period of time. A pilot …